Company profile

Ticker
LLY
Exchange
Website
CEO
David A. Ricks
Employees
Incorporated in
Location
Fiscal year end
Former names
Lilly Eli & Co, Lilly Eli & Co Et Al
SEC CIK
IRS number
350470950

LLY stock data

(
)
FINRA relative short interest over last month (20 trading days) ?

Calendar

1 May 20
4 Jun 20
31 Dec 20

News

Company financial data Financial data

Quarter (USD) Mar 20 Dec 19 Sep 19 Jun 19
Revenue 5.86B 6.11B 5.48B 5.64B
Net income 1.46B 1.5B 1.25B 1.33B
Diluted EPS 1.6 1.64 1.37 1.44
Net profit margin 24.86% 24.46% 22.90% 23.55%
Net change in cash -638.5M 253.8M
Cash on hand 1.7B 2.34B 2.29B
Cost of revenue 1.22B 1.28B 1.18B 1.12B
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue 22.32B 21.49B 19.97B 21.22B
Net income 8.32B 3.23B -204.1M 2.74B
Diluted EPS 8.89 3.13 -0.19 2.58
Net profit margin 37.27% 15.04% -1.02% 12.90%
Net change in cash -4.98B 784.5M 1.95B 915.7M
Cash on hand 2.34B 7.32B 6.54B 4.58B
Cost of revenue 4.72B 4.68B 4.45B 5.71B

Financial data from company earnings reports

Date Owner Security Transaction Code $Price #Shares $Value #Remaining
18 May 20 Tai Jackson P Common Stock Grant Aquire A 157.96 12 1.9K 58,200
27 Apr 20 Lilly Endowment Common Stock Sell Dispose S 163.6038 12,663 2.07M 112,197,641
24 Apr 20 Lilly Endowment Common Stock Sell Dispose S 163.99 4,200 688.76K 112,210,304
24 Apr 20 Lilly Endowment Common Stock Sell Dispose S 163.0536 118,958 19.4M 112,214,504
24 Apr 20 Lilly Endowment Common Stock Sell Dispose S 162.1783 47,225 7.66M 112,333,462
24 Apr 20 Lilly Endowment Common Stock Sell Dispose S 161.2161 49,617 8M 112,380,687
23 Apr 20 Lilly Endowment Common Stock Sell Dispose S 161.984 16,709 2.71M 112,430,304
23 Apr 20 Lilly Endowment Common Stock Sell Dispose S 160.898 20,831 3.35M 112,447,013
23 Apr 20 Lilly Endowment Common Stock Sell Dispose S 160.1387 125,314 20.07M 112,467,844
23 Apr 20 Lilly Endowment Common Stock Sell Dispose S 159.3648 67,146 10.7M 112,593,158
77.2% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1629 1633 -0.2%
Opened positions 124 234 -47.0%
Closed positions 128 97 +32.0%
Increased positions 537 508 +5.7%
Reduced positions 644 573 +12.4%
13F shares
Current Prev Q Change
Total value 1.06T 994.91B +6.1%
Total shares 738.8M 745.11M -0.8%
Total puts 4M 4.79M -16.6%
Total calls 3.94M 4.04M -2.5%
Total put/call ratio 1.0 1.2 -14.5%
Largest owners
Shares Value Change
Lilly Endowment 113.27M $15.71B -1.1%
Vanguard 72.68M $10.08B +2.5%
BLK BlackRock 64.3M $8.92B +5.6%
Primecap Management 41.94M $5.82B -2.8%
STT State Street 37.05M $5.14B -0.3%
Wellington Management 36.02M $5B -18.8%
FMR 28.04M $3.89B +97.0%
Capital International Investors 22.78M $3.16B -12.6%
State Farm Mutual Automobile Insurance 18.62M $2.58B 0.0%
JPM JPMorgan Chase & Co. 17.36M $2.41B -6.9%
Largest transactions
Shares Bought/sold Change
FMR 28.04M +13.8M +97.0%
Norges Bank 0 -8.91M EXIT
Wellington Management 36.02M -8.32M -18.8%
Dodge & Cox 291.51K -7.8M -96.4%
Jennison Associates 10.19M +5.68M +125.9%
BLK BlackRock 64.3M +3.42M +5.6%
Capital International Investors 22.78M -3.28M -12.6%
BAC Bank of America 11.14M +3.02M +37.2%
AMP Ameriprise Financial 5.69M +2.35M +70.4%
Vanguard 72.68M +1.76M +2.5%

Financial report summary

?
Management Discussion
  • Management’s discussion and analysis of results of operations and financial condition is intended to assist the reader in understanding and assessing significant changes and trends related to the results of operations and financial position of our consolidated company. This discussion and analysis should be read in conjunction with the consolidated condensed financial statements and accompanying footnotes in Item 1 of Part I of this Quarterly Report on Form 10-Q. Certain statements in this Item 2 of Part I of this Quarterly Report on Form 10-Q constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements" and "Risk Factors" in Part II, Item 1A of this Quarterly Report on Form 10-Q and Item 1A, “Risk Factors,” of Part I of our Annual Report on Form 10-K for the year ended December 31, 2019, may cause our actual results, financial position, and cash generated from operations to differ materially from these forward-looking statements.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: AbCellera, Aetna, Agency, Aid, alliance, Almirall, alongside, ankylosing, anxiety, Asymptomatic, attend, audit, axillary, burdened, Citrate, cloth, conciliation, conspiracy, coordinated, County, created, Crohn, CVS, deceptive, defense, degree, delayed, delaying, depression, depressive, depth, dermatology, Dermira, destocking, diabetic, DIAD, directed, disorder, dominantly, double, efficiently, enrollment, essential, evolving, exceed, excessive, experience, failure, fall, Fast, fibromyalgia, fiscal, focused, frequently, fulfill, gathering, glycopyrronium, halted, halting, harbor, inherited, installment, intensify, JPML, Judicial, jurisdiction, knowledge, lebrikizumab, lifesaving, likelihood, local, lung, Lyumjev, MDL, Medco, Medicinal, melanoma, modernized, multidistrict, musculoskeletal, narrative, neuropathic, neuroscience, obesity, Optum, originally, outbreak, outlined, pandemic, parallel, pausing, peak, people, peripheral, PGR, postponed, predicted, proceeding, produce, profitability, progression, prolonged, protracted, Qbrexza, quickly, rearranged, recession, reliable, rely, repaid, repatriation, repayment, resume, Roche, Rochester, safe, secondary, serve, Service, Sildenafil, Sitryx, speed, spread, stable, strain, subset, successfully, sued, surge, sweating, technical, temporarily, thyroid, timeline, Toll, topical, Track, transfection, transient, transmission, travel, Trijardy, Tyvyt, ulcerative, uncontrolled, underarm, unemployment, unlimited, unmet, unsuccessful, Viagra, Vitrakvi, world, Xeristar, XR
Removed: Adocia, affirming, alopecia, amended, American, ANDA, anguish, antibiotic, APP, applied, arbitration, areata, Avidity, Axiron, behalf, benign, Bipartisan, Blueprint, bring, Cadillac, checkpoint, chemotherapy, commencement, confirm, confirmatory, customary, deemed, demonstrated, denial, directly, discontinuing, discount, dismissal, dismissing, dispute, divestiture, dose, dysfunction, Eddingpharm, ehf, enacting, enactment, equipment, erectile, excise, exercise, exercised, framework, fraudulent, gap, hyperplasia, IIb, immaterial, implementation, implicit, inception, indemnify, injunction, injury, inventorship, Italy, Kingdom, language, lease, legacy, Ltda, mental, misappropriated, misrepresentation, misused, MMO, modified, Mutual, noncurrent, obtained, occurring, Ohio, package, Parenteral, passage, Pegilodecakin, PEGylated, personal, plaintiff, planned, practical, prepaid, procedurally, promotion, prostatic, Quimica, rebate, reclassification, reclassifying, recording, regulation, rejecting, released, remained, rent, respondent, retrospective, revised, revising, rheumatoid, salt, significantly, SLE, specialty, statute, study, suit, suspended, Suzhou, targeted, terminated, testosterone, Trump, tumor, unchanged, unit, Update, upholding, variable, White, wide, written